ArticleEye (London, England)2025
Assessment of the level of harm resulting from glaucoma progression due to review delay.
Article in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesReporting harm in monitoring delay for glaucoma patients is important but current guidance is limited. This study attempts to refine harm assessment using clinician expertise to identify the factors that should be considered in defining monitoring delay related harm.
methodsNational survey of glaucoma specialists through UK & Eire Glaucoma Society.
resultsFor perimetric harm, the importance of the severity of the reference visual field as well as the importance of locational loss (central and inferior visual field) in defining harm, were highlighted. Other factors such as only eye and loss of driving status should also be considered in defining harm. A delay of >50% was considered as the reference point for defining delay causing harm for the majority of respondents. For pre-perimetric delay there was less agreement on level of harm.
conclusionRecognising harm from glaucoma monitoring delay is important. However, it is a difficult process which is largely non-standardised. Harm itself should be defined by clinical deterioration (global and locational visual field loss) and psychological consequences. A strict definition of delay needs to be defined for the purpose of harm reporting. Other factors such as only eyed or loss of independence should also be considered when considering if harm has occurred.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.